• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

    2/2/24 3:16:44 PM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    SC 13G/A 1 xgna4_20224.htm COWEN FINANCIAL PRODUCTS LLC xgna4_20224.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*
    Exagen Inc.
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    30068x103
    (CUSIP Number)
    December 29, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 30068x103
           
    1
    NAME OF REPORTING PERSON
    Cowen Financial Products LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    27-0423711
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    898,630
    6
    SHARED VOTING POWER
    7
    SOLE DISPOSITIVE POWER
    898,630
    8
    SHARED DISPOSITIVE POWER
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    898,630
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.27%
    12
    TYPE OF REPORTING PERSON
    Passive Investor
    CUSIP No.: 30068x103
    ITEM 1(a). NAME OF ISSUER:
    Exagen Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    1261 Liberty Way
    Vista, CA 92081
    ITEM 2(a). NAME OF PERSON FILING:
    Cowen Financial Products LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    599 Lexington Ave
    New York, NY 10022
    ITEM 2(c). CITIZENSHIP:
    USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    30068x103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    898,630
    (b) Percent of class:
    5.27%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Cowen Financial Products LLC : 898,630
    (ii) shared power to vote or to direct the vote:
    Cowen Financial Products LLC :
    (iii) sole power to dispose or direct the disposition of:
    Cowen Financial Products LLC : 898,630
    (iv) shared power to dispose or to direct the disposition of:
    Cowen Financial Products LLC :
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 30068x103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 02 2024
    Cowen Financial Products LLC
    By:
    /s/ John Holmes
    Name:
    John Holmes
    Title:
    Chief Operating Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $XGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

      CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter's option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting u

      5/9/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Prices Public Offering of Common Stock

      CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satis

      5/8/25 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Proposed Public Offering of Common Stock

      CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exagen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Canac

      5/7/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/19/24 7:24:38 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/18/24 6:32:33 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      5/16/24 8:02:50 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exagen downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight

      8/5/22 9:00:50 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Keybanc reiterated coverage on Exagen with a new price target

      Keybanc reiterated coverage of Exagen with a rating of Overweight and set a new price target of $30.00 from $33.00 previously

      11/11/21 4:33:21 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Exagen with a new price target

      Cowen resumed coverage of Exagen with a rating of Outperform and set a new price target of $26.00

      10/15/21 7:34:02 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

      CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

      8/1/24 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Changes to the Board of Directors

      CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief

      4/26/24 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Appoints Paul Kim to Board of Directors

      SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public

      7/24/23 4:05:00 PM ET
      $FLGT
      $XGN
      Medical Specialities
      Health Care

    $XGN
    SEC Filings

    See more
    • SEC Form S-8 filed by Exagen Inc.

      S-8 - EXAGEN INC. (0001274737) (Filer)

      5/20/25 4:43:58 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Exagen Inc.

      8-K - EXAGEN INC. (0001274737) (Filer)

      5/9/25 4:05:59 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 424B5 filed by Exagen Inc.

      424B5 - EXAGEN INC. (0001274737) (Filer)

      5/8/25 4:08:47 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nmsic Co-Investment Fund, L.P. sold $1,155,000 worth of shares (350,000 units at $3.30) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      3/27/25 4:15:57 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John was granted 8,621 shares, increasing direct ownership by 1% to 746,214 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      3/4/25 6:48:32 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Chief Financial Officer Black Jeffrey G. was granted 15,000 shares, increasing direct ownership by 5% to 289,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      2/25/25 8:59:29 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exagen Inc.

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      12/12/24 5:00:54 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 2:42:55 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 7:12:55 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Financials

    Live finance-specific insights

    See more
    • Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

      CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.   Three Months Ended March 31,   2025   2024 (in thousands, except ASP data)  Revenue $15,498  $14,415 Gross margin  58.9%  59.6%Operating expenses $12,488  $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalents $11,194  $27,267 Trailing-twelve-month average selling price (ASP) $419  $377           Q1 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $15.5 million

      5/5/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

      4/21/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

      Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.   Three Months Ended December 31, Year Ended December 31,   2024   2024 (in thousands, except ASP data)  Revenue $13,655  $55,641 Gross margin  62.1%  59.5%Operating expenses $11,860  $46,748 Loss from operations $(3,383) $(13,636)Net los

      3/11/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care